Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate t... - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
From www.ncbi.nlm.nih.gov - January 17, 2017 8:18 AM
J Am Acad Dermatol. 2016 Dec 29. pii: S0190-9622(16)31158-6. doi: 10.1016/j.jaad.2016.11.042. [Epub ahead of print]